ProQR Therapeutics (NASDAQ:PRQR) Earns Outperform Rating from Analysts at Evercore ISI

Evercore ISI assumed coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research report report published on Tuesday morning, MarketBeat.com reports. The firm issued an outperform rating and a $5.00 target price on the biopharmaceutical company’s stock.

A number of other research analysts have also recently issued reports on the stock. Chardan Capital reissued a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday, March 14th. Oppenheimer assumed coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 price target on the stock. HC Wainwright upped their price objective on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, March 14th. Finally, Citigroup upgraded ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.75.

ProQR Therapeutics Stock Up 3.6 %

PRQR stock opened at $1.72 on Tuesday. The company has a market cap of $180.97 million, a PE ratio of -5.38 and a beta of 0.25. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.62. The business has a 50-day simple moving average of $1.56 and a 200 day simple moving average of $2.49.

Hedge Funds Weigh In On ProQR Therapeutics

Large investors have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in shares of ProQR Therapeutics by 11.8% during the fourth quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company’s stock worth $217,000 after purchasing an additional 8,621 shares during the last quarter. Jane Street Group LLC bought a new stake in ProQR Therapeutics during the 4th quarter worth approximately $30,000. Squarepoint Ops LLC raised its stake in shares of ProQR Therapeutics by 16.3% during the fourth quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 11,623 shares during the last quarter. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth $32,000. Finally, OneDigital Investment Advisors LLC grew its stake in shares of ProQR Therapeutics by 45.5% in the first quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 12,500 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).